Kidney; Complications, Allograft Clinical Trial
— PROTECTOfficial title:
To Evaluate Prevention Effect Of Everolimus and Low-dose Tacrolimus in Comparison With Standard-dose Tacrolimus Therapy With Mycophenolic Acid on the New Onset Diabetes Mellitus After Transplantation in the Renal Allograft Recipients
| Verified date | September 2014 |
| Source | Seoul St. Mary's Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Korea: Food and Drug Administration |
| Study type | Interventional |
To evaluate prevention effect of combination therapy of Everolimus and low-dose Tacrolimus in comparison with standard-dose Tacrolimus therapy with Mycophenolic acid on the New Onset Diabetes Mellitus after transplantation in the renal allograft recipients
| Status | Recruiting |
| Enrollment | 234 |
| Est. completion date | December 2015 |
| Est. primary completion date | December 2015 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 20 Years and older |
| Eligibility |
Inclusion Criteria: 1. Age = 20 year old 2. At least 3 months after kidney transplantation 3. Subject who is using Tacrolimus ± purine synthesis inhibitor + steroid without change within the past 3 months (except the dosage) 4. MDRD eGFR = 50 mL/min or serum creatinine < 2.0mg/dL within the past 3 months in the 6months after kidney transplantation 5. Rate of change of serum creatinine < +30% within the past 3 months in the 6months after kidney transplantation (if serum creatinine decreased, without rate of change is inclusion possible. if serum creatinine result was normal,regardless of the rate of change is able to register.) 6. Urine protein/creatinine ratio < 1g/g Cr (spot urine) Subject who is not applicable to the diagnostic criteria NODAT on 7. the baseline in the 6months after kidney transplantation 8. Subjects who agree with written informed consent Exclusion Criteria: 1. Subjects who received combined non-renal transplantation 2. Subject who received re-transplantation 3. ABO blood group incompatible(when anti-ABO Antibody titer <1:128 is inclusion possible.) 4. Sensitized patients before transplantation - Pretransplant or peak PRA titer > 50% - Pretransplant T cell cytotoxicity crossmatch (+) 5. HLA-identical living related donor 6. Subject who has diabetes mellitus / NODAT before transplantation 7. Subject who has suffered acute rejection episode within the past 3 months in the 6months after kidney transplantation 8. Subject with hypersensitivity to everolimus 9. Subject who should continue nephrotoxic drug until enrollment (Aminoglycoside, amphotericin B, cisplatin) 10. Subject with GI disorder that might interfere with the ability to absorb oral medication. (eg, gastrectomy or insufficiently treated diabetic gastroenteropathy) 11. Subjects with active peptic ulcer 12. HIV, HBsAg, or HCV Ab tests (+) 13. Abnormal liver function test (AST or ALT or total bilirubin> upper normal limit x3) 14. ANC <1.5*109/L or WBC <2.5*109/L or platelet <75*109/L 15. Treatment with an investigational drug within 30 days preceding the first dose of trial medication 16. Women who are either pregnant, lactating, planning to become pregnant in the next 12 months. 17. Subjects with history of cancer(except successfully treated), localized nonmelanocytic skin cancer, PTLD(Post-transplant lymphoproliferative disorder) 18. Subjects with clinically significant infections within the past 4 weeks in the 6months after kidney transplantation 19. Subjects who took major surgery within the past 4 weeks in the 6months after kidney transplantation |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
| Country | Name | City | State |
|---|---|---|---|
| Korea, Republic of | division of nephrology;Seoul St Mary's Hospital | Seoul |
| Lead Sponsor | Collaborator |
|---|---|
| Seoul St. Mary's Hospital | Novartis |
Korea, Republic of,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change from Baseline in Development of NODAT (Fasting glucose = 126 mg/dL, Random glucose = 200 mg/dL) at 12 months | To evaluate prevention effect of combination therapy of Everolimus and low-dose Tacrolimus in comparison with standard-dose Tacrolimus therapy with Mycophenolic acid on the New Onset Diabetes Mellitus after transplantation at 12 months after date of randomization. | 0 to 12 month | No |
| Secondary | Insulin resistance by HOMA-IR | Change from Baseline(V2) in Insulin resistance by HOMA-IR at 12months(V6) | 0 to 12 months | No |
| Secondary | Insulin secretion by HOMA-beta | Change from Baseline(V2) in insulin secretion by HOMA-beta at 12 months(V6) | 0 to 12 months | No |
| Secondary | OGTT (Fasting and PP2hr) | Change from baseline in OGTT (Fasting and PP2hr) at 12 months(V6) | 0 to 12 months | No |
| Secondary | Needs for anti-diabetic medication or insulin | Needs for anti-diabetic medication or insulin at Baseline(V2) | at Baseline(V2) | No |
| Secondary | Needs for anti-diabetic medication or insulin at 3 month(V3) | Needs for anti-diabetic medication or insulin at 3 month(V3) | at 3 month(V3) | No |
| Secondary | Needs for anti-diabetic medication or insulin at 6 month(V4) | Needs for anti-diabetic medication or insulin at 6 month(V4) | at 6 month(V4) | No |
| Secondary | Needs for anti-diabetic medication or insulin at 9 month(V5) | Needs for anti-diabetic medication or insulin at 9 month(V5) | at 9 month(V5) | No |
| Secondary | Needs for anti-diabetic medication or insulin at 12 month(V6) | Needs for anti-diabetic medication or insulin at 12 month(V6) | at 12 month(V6) | No |
| Secondary | Creatinine clearance (MDRD eGFR) at Baseline(V2) | Creatinine clearance (MDRD eGFR) at Baseline(V2) | at Baseline(V2) | No |
| Secondary | Creatinine clearance (MDRD eGFR) at 3 month(V3) | Creatinine clearance (MDRD eGFR) at 3 month(V3) | at 3 month(V3) | No |
| Secondary | Creatinine clearance (MDRD eGFR) at 6 month(V4) | Creatinine clearance (MDRD eGFR) at 6 month(V4) | at 6 month(V4) | No |
| Secondary | Creatinine clearance (MDRD eGFR) at 9 month(V5) | Creatinine clearance (MDRD eGFR) at 9 month(V5) | at 9 month(V5) | No |
| Secondary | Creatinine clearance (MDRD eGFR) at 12 month(V6) | Creatinine clearance (MDRD eGFR) at 12 month(V6) | at 12 month(V6) | No |
| Secondary | 12 month graft survival | After date of randomization, evaluate graft survival rate at 12 months(V6) | at 12 months(V6) | No |
| Secondary | 12 month patient survival rate | After date of randomization, evaluate patient survival rate at 12 months(V6) | at 12 months(V6) | No |
| Secondary | Change from baseline in Microalbuminuria(MAU) at 12 months | Change from baseline in Microalbuminuria(MAU) at 12 months | at 12 months(V6) | No |
| Secondary | Proportion of patients with significant proteinuria greater than 1g/gCr at Baseline(V2) | Proportion of patients with significant proteinuria greater than 1g/gCr at Baseline(V2) | at Baseline(V2) | No |
| Secondary | Proportion of patients with significant proteinuria greater than 1g/gCr at 3 month(V3) | Proportion of patients with significant proteinuria greater than 1g/gCr at 3 month(V3) | at 3 month(V3) | No |
| Secondary | Proportion of patients with significant proteinuria greater than 1g/gCr at 6 month(V4) | Proportion of patients with significant proteinuria greater than 1g/gCr at 6 month(V4) | at 6 month(V4) | No |
| Secondary | Proportion of patients with significant proteinuria greater than 1g/gCr at 9 month(V5) | Proportion of patients with significant proteinuria greater than 1g/gCr at 9 month(V5) | at 9 month(V5) | No |
| Secondary | Proportion of patients with significant proteinuria greater than 1g/gCr at 12 month(V6) | Proportion of patients with significant proteinuria greater than 1g/gCr at 12 month(V6) | at 12 month(V6) | No |
| Secondary | Number of episode of biopsy proven acute rejection (BPAR) | Cumulative incidence rate of Biopsy Proven Acute Rejection(BPAR) at 12months(V6) after date of randomization. | at 12 month(V6) | No |
| Secondary | Number of hospitalization of any cause (except admission for protocol biopsy) at Baseline(V2) | Number of hospitalization of any cause (except admission for protocol biopsy) at Baseline(V2) | at Baseline(V2) | No |
| Secondary | Number of hospitalization of any cause (except admission for protocol biopsy) at 3 month(V3) | Number of hospitalization of any cause (except admission for protocol biopsy) at 3 month(V3) | at 3 month(V3) | No |
| Secondary | Number of hospitalization of any cause (except admission for protocol biopsy) at 6 month(V4) | Number of hospitalization of any cause (except admission for protocol biopsy) at 6 month(V4) | at 6 month(V4) | No |
| Secondary | Number of hospitalization of any cause (except admission for protocol biopsy) at 9 month(V5) | Number of hospitalization of any cause (except admission for protocol biopsy) at 9 month(V5) | at 9 month(V5) | No |
| Secondary | Number of hospitalization of any cause (except admission for protocol biopsy) at 12 month(V6) | Number of hospitalization of any cause (except admission for protocol biopsy) at 12 month(V6) | at 12 month(V6) | No |
| Secondary | Number of opportunistic infections (BKVN) at Baseline(V2) | Number of opportunistic infections (BKVN) at Baseline(V2) | at Baseline(V2) | No |
| Secondary | Number of opportunistic infections (BKVN) at 12month(V6) | Number of opportunistic infections (BKVN) at 12month(V6) | at 12 month(V6) | No |
| Secondary | Prevalence of NODAT at Baseline(V2) | Prevalence of NODAT at Baseline(V2) | at Baseline(V2) | No |
| Secondary | Prevalence of NODAT at 3 month(V3) | Prevalence of NODAT at 3 month(V3) | at 3 month(V3) | No |
| Secondary | Prevalence of NODAT at 6 month(V4) | Prevalence of NODAT at 6 month(V4) | at 6 month(V4) | No |
| Secondary | Prevalence of NODAT at 9 month (V5) | Prevalence of NODAT at 9 month (V5) | at 9 month (V5) | No |
| Secondary | Prevalence of NODAT at 12 month(V6) | Prevalence of NODAT at 12 month(V6) | at 12 month(V6) | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01327573 -
Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation
|
Phase 1 | |
| Completed |
NCT02294032 -
The Role of B Cells in Kidney Allograft Dysfunction
|